UroGen Pharma Ltd.URGNNASDAQ
LOADING
|||
Year-over-year operating income growth rate
| Period | Value |
|---|---|
| Q3 2025 | 0.00% |
| Q2 2025 | 100.00% |
| Q1 2025 | -33.47% |
| Q4 2024 | -57.64% |
| Q3 2024 | 32.10% |
| Q2 2024 | -0.38% |
| Q1 2024 | -76.19% |
| Q4 2023 | -8.21% |
| Q3 2023 | 12.24% |
| Q2 2023 | 30.22% |
| Q1 2023 | -8.69% |
| Q4 2022 | -12.14% |
| Q3 2022 | 3.36% |
| Q2 2022 | 14.77% |
| Q1 2022 | -10.25% |
| Q4 2021 | 15.04% |
| Q3 2021 | -2.70% |
| Q2 2021 | 12.60% |
| Q1 2021 | 4.18% |
| Q4 2020 | 6.42% |
| Q3 2020 | 8.42% |
| Q2 2020 | 17.53% |
| Q1 2020 | 3.21% |
| Q4 2019 | -69.87% |
| Q3 2019 | 1.26% |
| Q2 2019 | -5.88% |
| Q1 2019 | 6.60% |
| Q4 2018 | -13.88% |
| Q3 2018 | -14.40% |
| Q2 2018 | -35.15% |
| Q1 2018 | -34.28% |
| Q4 2017 | -3252.48% |
| Q3 2017 | 94.91% |
| Q2 2017 | -68.20% |
| Q1 2017 | -125.45% |
| Q4 2016 | 327.51% |
| Q3 2016 | -79.97% |
| Q2 2016 | 5.64% |
| Q1 2016 | 48.33% |
| Q4 2015 | 0.00% |